|
AT500379B8
(de)
|
2001-02-02 |
2009-08-15 |
Axon Neuroscience |
Tau-proteine
|
|
WO2004007722A2
(en)
*
|
2002-07-12 |
2004-01-22 |
Axon Neuroscience Forschungs- Und Entwicklungs Gmbh |
Transgenic animal expressing alzheimer’s tau protein
|
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
|
RU2442793C2
(ru)
|
2005-11-30 |
2012-02-20 |
Эбботт Лэборетриз |
АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
|
|
PL1976877T5
(pl)
|
2005-11-30 |
2017-09-29 |
Abbvie Inc |
Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
|
|
ES2321996B1
(es)
*
|
2006-01-26 |
2010-03-05 |
Consejo Superior Investig. Cientificas |
Uso de compuestos que se unen al dominio de union a microtubulos de tau en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y su aplicacion en el tratamiento de tauopatias.
|
|
US8012936B2
(en)
*
|
2006-03-29 |
2011-09-06 |
New York University |
Tau fragments for immunotherapy
|
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
|
US8895004B2
(en)
|
2007-02-27 |
2014-11-25 |
AbbVie Deutschland GmbH & Co. KG |
Method for the treatment of amyloidoses
|
|
WO2009143556A1
(en)
*
|
2008-05-30 |
2009-12-03 |
The University Of Sydney |
TREATMENTS FOR EXCITOTOXICITY AND Aß-MEDIATED TOXICITY AND AGE-ASSOCIATED NEURONAL DYSFUNCTION
|
|
EP4218794A3
(en)
*
|
2009-06-10 |
2023-09-13 |
New York University |
Immunological targeting of pathological tau proteins
|
|
US8609097B2
(en)
*
|
2009-06-10 |
2013-12-17 |
Hoffmann-La Roche Inc. |
Use of an anti-Tau pS422 antibody for the treatment of brain diseases
|
|
EP2470211B1
(en)
*
|
2009-08-28 |
2016-01-27 |
The Board of Regents of The University of Texas System |
Antibodies that bind tau oligomers
|
|
US10266585B2
(en)
|
2009-08-28 |
2019-04-23 |
The Board Of Regents Of The Univerity Of Texas System |
Methods of treating brain injury
|
|
WO2011130377A2
(en)
|
2010-04-15 |
2011-10-20 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
|
ITRM20100320A1
(it)
|
2010-06-11 |
2011-12-11 |
Consiglio Nazionale Ricerche |
Metodo per la diagnostica e il trattamento delle taupatie
|
|
US9062101B2
(en)
|
2010-08-14 |
2015-06-23 |
AbbVie Deutschland GmbH & Co. KG |
Amyloid-beta binding proteins
|
|
LT2627672T
(lt)
|
2010-10-11 |
2018-12-10 |
Biogen International Neuroscience Gmbh |
Žmogaus antikūnai prieš tau baltymą
|
|
CA2817973C
(en)
|
2010-10-15 |
2019-06-25 |
The Board Of Regents Of The University Of Texas System |
Antibodies that bind amyloid oligomers
|
|
WO2012106363A2
(en)
|
2011-01-31 |
2012-08-09 |
Intellect Neurosciences Inc. |
Treatment of tauopathies
|
|
WO2012162179A1
(en)
*
|
2011-05-20 |
2012-11-29 |
Oligomerix, Inc. |
Tau protease compositions and methods of use
|
|
EP3275461A1
(en)
*
|
2011-09-19 |
2018-01-31 |
Axon Neuroscience SE |
Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field
|
|
JP6358953B2
(ja)
|
2011-10-07 |
2018-07-18 |
エーシー イミューン エス.エー. |
タウを認識するホスホ特異的抗体
|
|
EP2870176A4
(en)
|
2012-07-03 |
2016-09-28 |
Univ Washington |
ANTIBODIES DIRECTED AGAINST TAU
|
|
EP2885010B1
(en)
|
2012-08-16 |
2020-01-01 |
Ipierian, Inc. |
Methods of treating a tauopathy
|
|
US9200068B2
(en)
*
|
2012-12-18 |
2015-12-01 |
Regents Of The University Of Minnesota |
Compositions and methods related to tauopathy
|
|
JP6284548B2
(ja)
|
2012-12-21 |
2018-02-28 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
ヒト抗タウ抗体
|
|
US8980270B2
(en)
|
2013-01-18 |
2015-03-17 |
Ipierian, Inc. |
Methods of treating a tauopathy
|
|
WO2014165271A2
(en)
|
2013-03-13 |
2014-10-09 |
Neotope Biosciences Limited |
Tau immunotherapy
|
|
MX374811B
(es)
*
|
2013-03-15 |
2025-03-06 |
Ac Immune Sa |
Anticuerpos anti-tau y métodos de uso.
|
|
CR20160270A
(es)
|
2013-12-20 |
2016-09-05 |
Hoffmann La Roche |
ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
|
|
CN105939722A
(zh)
|
2014-02-14 |
2016-09-14 |
伊皮埃里安股份有限公司 |
Tau肽,抗Tau抗体,及其使用方法
|
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
|
TWI734975B
(zh)
*
|
2014-06-27 |
2021-08-01 |
美商C2N醫療診斷有限責任公司 |
人類化抗-tau抗體
|
|
EP3166688B1
(en)
|
2014-07-08 |
2024-08-21 |
New York University |
Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
|
|
AR103713A1
(es)
|
2015-02-26 |
2017-05-31 |
Lilly Co Eli |
Anticuerpos contra tau y sus usos
|
|
NZ775762A
(en)
*
|
2015-06-05 |
2025-02-28 |
Genentech Inc |
Anti-tau antibodies and methods of use
|
|
ES2809728T3
(es)
|
2015-06-24 |
2021-03-05 |
Hoffmann La Roche |
Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
|
|
SG10202010735PA
(en)
|
2015-07-06 |
2020-11-27 |
UCB Biopharma SRL |
Tau-binding antibodies
|
|
US10988528B2
(en)
|
2015-08-13 |
2021-04-27 |
New York University |
Antibody-based molecules specific for the truncated ASP421 epitope of Tau and their uses in the diagnosis and treatment of tauopathy
|
|
EP3452507B1
(en)
|
2016-05-02 |
2022-10-19 |
Prothena Biosciences Limited |
Tau immunotherapy
|
|
MX2018013384A
(es)
|
2016-05-02 |
2019-02-28 |
Prothena Biosciences Ltd |
Anticuerpos que reconocen tau.
|
|
JP7029415B2
(ja)
*
|
2016-07-12 |
2022-03-03 |
ハー・ルンドベック・アクチエゼルスカベット |
過リン酸化タウに特異的な抗体およびその使用方法
|
|
JP6949102B2
(ja)
|
2016-08-09 |
2021-10-13 |
イーライ リリー アンド カンパニー |
併用療法
|
|
EP3551220B1
(en)
|
2016-12-07 |
2025-01-29 |
Genentech, Inc. |
Anti-tau antibodies and methods of use
|
|
EP3551655A2
(en)
|
2016-12-07 |
2019-10-16 |
Genentech, Inc. |
Anti-tau antibodies and methods of their use
|
|
SG11201910066QA
(en)
|
2017-05-02 |
2019-11-28 |
Prothena Biosciences Ltd |
Antibodies recognizing tau
|
|
CN111201030B
(zh)
|
2017-07-25 |
2024-11-01 |
真和制药有限公司 |
通过阻断tim-3和其配体的相互作用治疗癌症
|
|
CN107686839B
(zh)
*
|
2017-09-25 |
2020-12-04 |
安徽朵能生物科技有限公司 |
微管结合蛋白cript、其治疗性突变体及其应用
|
|
EP3829634A1
(en)
|
2018-07-31 |
2021-06-09 |
Eli Lilly and Company |
Combination therapy
|
|
KR20210124308A
(ko)
|
2019-01-30 |
2021-10-14 |
트루바인딩 아이엔씨. |
항-gal3 항체 및 이의 용도
|
|
TWI859197B
(zh)
|
2019-03-03 |
2024-10-21 |
愛爾蘭商普羅帝納生物科學公司 |
識別tau之抗體
|
|
EP4317950B1
(en)
|
2019-03-18 |
2026-01-28 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas screening platform to identify genetic modifiers of tau seeding or aggregation
|
|
CN113874078B
(zh)
|
2019-04-05 |
2025-05-06 |
Tauc3生物制品有限公司 |
抗tauc3抗体及其应用
|
|
GB2585252A
(en)
|
2019-07-05 |
2021-01-06 |
Gen2 Neuroscience Ltd |
Tau epitope and binding molecules
|
|
MX2022014786A
(es)
|
2020-05-26 |
2023-01-16 |
Truebinding Inc |
Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
|
|
US20240101654A1
(en)
|
2020-12-29 |
2024-03-28 |
Neurimmune Ag |
Human anti-tau antibodies
|
|
WO2026102093A1
(en)
|
2024-11-07 |
2026-05-15 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|